Denali Therapeutics Inc. (DNLI) Financial Statements (2025 and earlier)

Company Profile

Business Address 161 OYSTER POINT BLVD.
SOUTH SAN FRANCISCO, CA 94080
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments817,926,000832,331,000836,559,000896,044,000936,869,0001,034,511,000
Cash and cash equivalent56,947,000174,960,00090,636,00074,679,00060,574,000127,106,000
Short-term investments760,979,000657,371,000745,923,000821,365,000876,295,000907,405,000
Other undisclosed current assets60,712,00032,105,00032,280,00032,339,00036,706,00029,626,000
Total current assets:878,638,000864,436,000868,839,000928,383,000973,575,0001,064,137,000
Noncurrent Assets
Finance lease, right-of-use asset, after accumulated amortization50,199,00047,533,00038,685,000   
Operating lease, right-of-use asset21,963,00022,861,00023,717,00024,533,00025,309,00026,048,000
Property, plant and equipment57,765,00055,236,00050,822,00048,077,00046,863,00045,589,000
Long-term investments and receivables235,844,000359,373,000445,463,000450,994,000490,723,000 
Long-term investments235,844,000359,373,000445,463,000450,994,000490,723,000 
Other noncurrent assets26,934,00024,741,00026,487,00050,578,00044,621,00018,143,000
Total noncurrent assets:392,705,000509,744,000585,174,000574,182,000607,516,00089,780,000
TOTAL ASSETS:1,271,343,0001,374,180,0001,454,013,0001,502,565,0001,581,091,0001,153,917,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities15,812,000102,208,00014,423,00019,949,00017,841,00077,982,000
Accounts payable8,458,00011,137,0009,594,00013,936,00011,855,0009,483,000
Accrued liabilities7,354,00091,071,0004,829,0006,013,0005,986,00068,499,000
Other undisclosed current liabilities76,065,000 72,670,00054,584,00064,741,000 
Total current liabilities:91,877,000102,208,00087,093,00074,533,00082,582,00077,982,000
Noncurrent Liabilities
Long-term debt and lease obligation5,598,0005,615,0005,631,000   
Finance lease, liability5,598,0005,615,0005,631,000   
Liabilities, other than long-term debt34,449,00036,673,00038,850,00040,981,00043,034,00044,981,000
Operating lease, liability34,449,00036,673,00038,850,00040,981,00043,034,00044,981,000
Other undisclosed noncurrent liabilities16,733,000 3,944,000   
Total noncurrent liabilities:56,780,00042,288,00048,425,00040,981,00043,034,00044,981,000
Total liabilities:148,657,000144,496,000135,518,000115,514,000125,616,000122,963,000
Equity
Equity, attributable to parent, including:1,122,686,0001,229,684,0001,318,495,0001,387,051,0001,455,475,0001,030,954,000
Common stock      1,711,000
Additional paid in capital2,790,825,0002,764,880,0002,735,433,0002,704,992,0002,673,033,0002,144,811,000
Accumulated other comprehensive income (loss)2,037,0002,020,0005,529,000(2,659,000)(1,296,000)643,000
Accumulated deficit(1,671,954,000)(1,538,984,000)(1,424,231,000)(1,317,039,000)(1,218,013,000)(1,116,211,000)
Other undisclosed equity, attributable to parent1,778,0001,768,0001,764,0001,757,0001,751,000 
Total equity:1,122,686,0001,229,684,0001,318,495,0001,387,051,0001,455,475,0001,030,954,000
TOTAL LIABILITIES AND EQUITY:1,271,343,0001,374,180,0001,454,013,0001,502,565,0001,581,091,0001,153,917,000

Income Statement (P&L) (USD)

6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
Operating expenses(145,580,000)(129,846,000)(123,187,000)(116,593,000)(132,252,000)(132,572,000)
Other undisclosed operating income     14,537,000 
Operating loss:(145,580,000)(129,846,000)(123,187,000)(116,593,000)(117,715,000)(132,572,000)
Nonoperating income      13,129,000
Investment income, nonoperating      12,243,000
Interest and debt expense(200,000)(200,000)(100,000)   
Loss from continuing operations before income taxes:(145,780,000)(130,046,000)(123,287,000)(116,593,000)(117,715,000)(119,443,000)
Other undisclosed loss from continuing operations  (68,000)   (30,000)
Net loss:(145,780,000)(130,114,000)(123,287,000)(116,593,000)(117,715,000)(119,473,000)
Other undisclosed net income attributable to parent12,810,00015,361,00016,095,00017,567,00015,913,000 
Net loss available to common stockholders, diluted:(132,970,000)(114,753,000)(107,192,000)(99,026,000)(101,802,000)(119,473,000)

Comprehensive Income (USD)

6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
Net loss:(145,780,000)(130,114,000)(123,287,000)(116,593,000)(117,715,000)(119,473,000)
Comprehensive loss:(145,780,000)(130,114,000)(123,287,000)(116,593,000)(117,715,000)(119,473,000)
Other undisclosed comprehensive income, net of tax, attributable to parent12,827,00011,852,00024,283,00016,204,00013,974,0001,294,000
Comprehensive loss, net of tax, attributable to parent:(132,953,000)(118,262,000)(99,004,000)(100,389,000)(103,741,000)(118,179,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: